Development of PARP and Immune-Checkpoint Inhibitor Combinations
PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 2018-12, Vol.78 (24), p.6717-6725 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6725 |
|---|---|
| container_issue | 24 |
| container_start_page | 6717 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 78 |
| creator | Stewart, Ross A Pilié, Patrick G Yap, Timothy A |
| description | PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development. |
| doi_str_mv | 10.1158/0008-5472.CAN-18-2652 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2141034912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2141034912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-7927d2e21e342a639023867ed1f6c4842340e809d6d6b96301c78bb399a1f5a3</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMobk5_gtJLbzJz8tXkzlG_BkOH7D6kbcqqbVObVvDf27Lp1eHlPO858CB0DWQJINQdIURhwWO6TFavGBSmUtATNAfBFI45F6do_s_M0EUIH2MUQMQ5mjHCtSKKzdH9g_t2lW9r1_SRL6Lt6n0b2SaP1nU9NA4ne5d9tr4ct-tmX6Zl77so8XVaNrYvfRMu0Vlhq-CujnOBdk-Pu-QFb96e18lqgzNOaY9jTeOcOgqOcWol04QyJWOXQyEzrjhlnDhFdC5zmWrJCGSxSlOmtYVCWLZAt4ezbee_Bhd6U5chc1VlG-eHYChwIIxroCMqDmjW-RA6V5i2K2vb_RggZnJnJi9m8mJGdwaUmdyNvZvjiyGtXf7f-pPFfgFc-Gg-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2141034912</pqid></control><display><type>article</type><title>Development of PARP and Immune-Checkpoint Inhibitor Combinations</title><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Stewart, Ross A ; Pilié, Patrick G ; Yap, Timothy A</creator><creatorcontrib>Stewart, Ross A ; Pilié, Patrick G ; Yap, Timothy A</creatorcontrib><description>PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.CAN-18-2652</identifier><identifier>PMID: 30498083</identifier><language>eng</language><publisher>United States</publisher><ispartof>Cancer research (Chicago, Ill.), 2018-12, Vol.78 (24), p.6717-6725</ispartof><rights>2018 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-7927d2e21e342a639023867ed1f6c4842340e809d6d6b96301c78bb399a1f5a3</citedby><cites>FETCH-LOGICAL-c422t-7927d2e21e342a639023867ed1f6c4842340e809d6d6b96301c78bb399a1f5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30498083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stewart, Ross A</creatorcontrib><creatorcontrib>Pilié, Patrick G</creatorcontrib><creatorcontrib>Yap, Timothy A</creatorcontrib><title>Development of PARP and Immune-Checkpoint Inhibitor Combinations</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.</description><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kF1LwzAUhoMobk5_gtJLbzJz8tXkzlG_BkOH7D6kbcqqbVObVvDf27Lp1eHlPO858CB0DWQJINQdIURhwWO6TFavGBSmUtATNAfBFI45F6do_s_M0EUIH2MUQMQ5mjHCtSKKzdH9g_t2lW9r1_SRL6Lt6n0b2SaP1nU9NA4ne5d9tr4ct-tmX6Zl77so8XVaNrYvfRMu0Vlhq-CujnOBdk-Pu-QFb96e18lqgzNOaY9jTeOcOgqOcWol04QyJWOXQyEzrjhlnDhFdC5zmWrJCGSxSlOmtYVCWLZAt4ezbee_Bhd6U5chc1VlG-eHYChwIIxroCMqDmjW-RA6V5i2K2vb_RggZnJnJi9m8mJGdwaUmdyNvZvjiyGtXf7f-pPFfgFc-Gg-</recordid><startdate>20181215</startdate><enddate>20181215</enddate><creator>Stewart, Ross A</creator><creator>Pilié, Patrick G</creator><creator>Yap, Timothy A</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181215</creationdate><title>Development of PARP and Immune-Checkpoint Inhibitor Combinations</title><author>Stewart, Ross A ; Pilié, Patrick G ; Yap, Timothy A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-7927d2e21e342a639023867ed1f6c4842340e809d6d6b96301c78bb399a1f5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stewart, Ross A</creatorcontrib><creatorcontrib>Pilié, Patrick G</creatorcontrib><creatorcontrib>Yap, Timothy A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stewart, Ross A</au><au>Pilié, Patrick G</au><au>Yap, Timothy A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of PARP and Immune-Checkpoint Inhibitor Combinations</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2018-12-15</date><risdate>2018</risdate><volume>78</volume><issue>24</issue><spage>6717</spage><epage>6725</epage><pages>6717-6725</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.</abstract><cop>United States</cop><pmid>30498083</pmid><doi>10.1158/0008-5472.CAN-18-2652</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 2018-12, Vol.78 (24), p.6717-6725 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2141034912 |
| source | American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| title | Development of PARP and Immune-Checkpoint Inhibitor Combinations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A31%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20PARP%20and%20Immune-Checkpoint%20Inhibitor%20Combinations&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Stewart,%20Ross%20A&rft.date=2018-12-15&rft.volume=78&rft.issue=24&rft.spage=6717&rft.epage=6725&rft.pages=6717-6725&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/0008-5472.CAN-18-2652&rft_dat=%3Cproquest_cross%3E2141034912%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2141034912&rft_id=info:pmid/30498083&rfr_iscdi=true |